NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares London, UK – 22 June 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced the closing of its…
NetScientific plc ("NetScientific", the "Group" or the "Company") NetScientific participates in PDS Biotechnology $45m equity issue and related party transaction London, UK – 16 June 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) yesterday announced an issue of c.5.3 million new shares of common stock…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Proposed Offering of Common Stock London, UK – 15 June 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced that it has commenced an underwritten public offering of shares of its common stock…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting London, UK – 8 June 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today announced…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting London, UK – 20 May 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) today announced publication of…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results London, UK – 13 May 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) today announced an update on business, as well as financial results for the…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting London, UK – 30 April 2021 - NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) yesterday announced that initial…
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Biotechnology Reports Final Results for the Full Year 2020 & Business Update London, UK – 18 March 2021 – NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced its financial results for the full year ended 31 December…
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS COVID-19 Vaccine Commercialisation Update c. $60m Funding Commitment by Brazilian government for Clinical Development and Commercialisation of PDS Consortium’s COVID-19 Vaccine London, UK – 11 March 2021 – NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that PDS Biotech’s proprietary Versamune® T-cell activating technology, today announced that its…
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS COVID-19 Vaccine Commercialisation Update Blanver joins PDS-Farmacore COVID-19 Vaccine Consortium PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine London, UK – 23 February 2021 – NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that Blanver Farmoquímica…
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.